Skip to Main Content

File this under “How low can you go?”

An updated analysis of Amgen’s (AMGN) Repatha, which is one of the newest cholesterol drugs, has been released and suggests the price would have to drop a whopping 85 percent to 88 percent off the existing list price of $14,500 in order to be considered cost effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED